BIBLIOGRAFÍA

Recopilación de las referencias bibliográficas de todos los artículos.

SEGURIDAD CARDIOVASCULAR DE LOS TRATAMIENTOS ANTIDIABÉTICOS

1. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
2. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
3. Kooy A, De Jager J, Lehert P, Bets D, Wulffelé MG, Donker AJ, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009;169:616-25.
4. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011;32:1900-8.
5. Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care 2010;33:1224-9.
6. Andersson C, Gislason GH, Jørgensen CH, Hansen PR, Vaag A, Sørensen R, et al. Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure. Diabetes Res Clin Pract 2011;94:119-25.
7. Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, et al. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes Obes Metab 2012;14:803-9.
8. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.
9. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
10. Standl E, Theodorakis MJ, Erbach M, Schnell O, Tuomilehto J. On the potential of acarbose to reduce cardiovascular disease. Cardiovasc Diabetol 2014;13:81.
11. Best JH, Hoogwerf BJ, Herman WH, Pelletier EM, Smith DB, Wenten M, et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 2011;34:90-5.
12. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26.
13. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Pérez AT, et al.; EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015;385:2067-76.
14. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al.; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-42.
15. McInnes G, Evans M, Del Prato S, Stumvoll M, Schweizer A, Lukashevich V, et al. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17000 patients. Diabetes Obes Metab 2015. doi: 10.1111/dom.12548. [Epub a head of print.]
16. McMurray J, et al. The Vildagliptin in Ventricular Dysfunction Diabetes trial (VIVIDD). ESC Lisboa; 2013.
17. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015. [Epub a head of print.]
18. Gilbert RE, Krum H. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet 2015;385:2107-17.

HERRAMIENTAS PARA LA REVISIÓN BIBLIOGRÁFICA: RSS, ALERTAS, BASES DE DATOS, MEDSCAPE... ¿DÓNDE BUSCAR? ¿CÓMO MANTENERSE AL DÍA?

1. González-González AI, Sánchez Mateos JF, Sanz Cuesta T, Riesgo Fuertes R, Escortell Mayor E, Hernández Fernández T. Estudio de las necesidades de información generadas por los médicos de atención primaria (proyecto ENIGMA). Aten Primaria 2006;38:219-24.
2. Louro González A, Fernández Obanza E, Fernández López E, Vázquez Millán P, Villegas González L, Casariego Vales E. Análisis de las dudas de los médicos de atención primaria. Aten Primaria 2009;41:592-7.
3. Barrera Linares E, Ávila de Tomás JF. Web 2.0 y otros recursos de Internet. Formación Médica Continuada en Atención Primaria 2011;18(6):321-9.
4. Hughes B, Joshi I, Lemonde H, Wareham J. Junior physician's use of Web 2.0 for information seeking and medical education: a qualitative study. Int J Med Inform 2009;78:645-55.
5. Dicenso A, Bayley L, Haynes RB. Accessing pre-appraised evidence: fine-tuning the 5S model into a 6S model. Evid Based Nurs 2009;12(4):99-101.

6. Barrera Linares E, Bartolomé Moreno C. PLE y web 2.0 para la gestión del conocimiento. Taller Semfyc 2015. Gijón. Disponible en: URL: https://sites.google.com/site/tallersemfyc2015. [Última consulta: 20 de julio de 2015].
7. María Tablado MA, Sagredo Pérez J, Jurado Otero M, Lagos Aguilar A. Papel de la diabetes mellitus en las redes sociales. Avances en Diabetología 2014;30(Espec Congr):71.

NUEVAS FORMAS DE APRENDIZAJE A TRAVÉS DEL JUEGO COMPETITIVO: LA EDUCACIÓN COMPETITIVA

1. Kinch MS, Haynesworth A, Kinch SL, Hoyer D. An overview of FDA-approved new molecular entities: 1827-2013. Drug Discov Today 2014;19(8):1033-9.
2. Kleinsinger F. Changing continuing medical education. JAMA 2015;314(10):1073-4.
3. Nissen SE. Reforming the continuing medical education system. JAMA 2015;313(18):1813-4.
4. Forsetlund L, Bjørndal A, Rashidian A, Jamtvedt G, O'Brien MA, Wolf F, et al. Continuing education meetings and workshops: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2009;(2):CD003030.
5. Competitividad y educación [citado el 28 de septiembre de 2015]. Recuperado a partir de: URL: http://www.eumed.net/cursecon/ecolat/ve/mta-Compe.htm.

INTENSIFICACIÓN CON MEZCLAS

- Ampudia-Blasco FJ, Rosenstocka J. Estrategias de insulinización en la diabetes mellitus tipo 2. Av Diabetol 2008;24(1):7-20.
- Buse JB, Wolffenbuttel BH, Herman WH, Hippler S, Martin SA, Jiang HH, et al.The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) trial: comparing the durability of lispro mix 75/25 and glargine. Diabetes Care 2011;34:249-55.
- Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, et al.; 4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetes N Engl J Med 2009;361:1736-47.
- Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, et al.; 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-30.
- Riddle MC, Rosenstock J, Vlajnic A, Gao L. Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections. Diabetes Obes Metab 2014;16:396-402.
- Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S.Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008;31:20-5.
- Rys P, Wojciechowski P, Rogoz-Sitek A, Niesyczyński G, Lis J, Syta A, et al. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. Acta Diabetol 2015;52:649-62.
- Tinahones FJ, Gross J, Onaca LA, Cleall S, Rodríguez A. Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial. Diabetes Obes Metab 2014;16(10):963-70.
- Wang C, Mamza J, Idris I. Systematic review or meta-analysis biphasic vs basal bolus insulin regimen in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabet Med 2015;32:585-94.

DEPRESCRIBIR EN DIABETES. EL FLAGRANTE CASO DE UN SEÑOR ANCIANO

1. Martínez Velilla N, Vilches Moraga A. Conferencia de consenso: Tratamiento de la diabetes tipo 2 en el paciente anciano. Med Clin (Barc) 2014;142:89-90.
2. Gómez Huelgas R, Díez-Espino J, Formiga F, Lafita Tejedor J, Rodríguez Mañas L, González-Sarmiento E, et al. Tratamiento de la diabetes tipo 2 en el paciente anciano. Med Clin (Barc) 2013;140:134. e1-e12.
3. American Geriatrics Society Expert Panel on Care of Older Adults with Diabetes Mellitus, Moreno G, Mangione CM, Kimbro L, Vaisberg E. Guidelines abstracted from the American Geriatrics Society Guidelines for Improving the Care of Older Adults with Diabetes Mellitus: 2013 update. J Am Geriatr Soc 2013;61:2020-6.
4. Sinclair A, Morley JE, Rodríguez-Manas L, Paolisso G, Bayer T, Zeyfang A, et al. Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J Am Med Dir Assoc 2012;13:497-502.

EL ABC DE LOS SISTEMAS DE MONITORIZACIÓN CONTINUA DE GLUCOSA Y DE LAS INFUSORAS SUBCUTÁNEAS DE INSULINA

- Bergenstal R, Ahmann AJ, Bailey T, Beck RW, Bissen J, BuckinghamB, et al. Recommendations for standardizing glucosereporting and analysis to optimize clinical decision making indiabetes: the Ambulatory Glucose profile (AGP). Diabetes Technol Therap 2013;15:198-211.

- Grunberger G, Bailey T, Cohen A, Flood TM, Handelsman Y, Hellman R, et al. Statement by the American Association of Clinical Endocrinologists Consensus Panel on insulin pump management. Endocr Pract 2010;16(5):746-62.
- LevyI, Jànsa M, Vidal M. Terapia con infusión subcutánea continua de insulina (ISCI): cálculo individualizado del «bolus» y de la línea basal. Av Diabetol 2005;21:32-7.
- Ruiz de Adana M, Rigla M, Vidal P. Consenso sobre el uso de la monitorización continua de glucosa. Av Diabetol 2009;1-3.
- Solá E. ¿De qué nos sirve evaluar las tendencias del perfil glucémico ambulatorio? Av Diabetol 2014;30(5):121-30.

DIABETES MELLITUS TIPO 2, FUNCIÓN PULMONAR Y RESPIRACIÓN DURANTE EL SUEÑO. ¿RESPIRAMOS DIABETES?

1. Sandler M. Is the lung a «target organ» in diabetes mellitus? Arch Intern Med 1990;150:1385-8.
2. Nicolaie T, Zavoianu C, Nuta P. Pulmonary involvement in diabetes mellitus. Rom J Intern Med 2003;41:365-74.
3. Weynand B, Jonckheere A, Frans A, Rahier J. Diabetes mellitus induces a thickening of the pulmonary basal lamina. Respiration 1999;66:14-9.
4. Yeh HC, Punjabi NM, Wang NY, Pankow JS, Duncan BB, Cox CE, et al. Cross-sectional and prospective study of lung function in adults with type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 2008;31:741-6.
5. Walter RE, Beiser A, Givelber RJ, O'Connor GT, Gottlieb DJ. Association between glycemic state and lung function. The Framingham Heart Study. Am J Respir Crit Care Med 2003;167:911-6.
6. Fariña J, Furió V, Fernández-Acereño MJ, Muzas MA. Nodular fibrosis of the lung in diabetes mellitus. Virchows Arch 1995;427:61-3.
7. Davis TME, Knuiman M, Kendall P, Vu H, Davis WA. Reduced pulmonary function and its associations in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Res Clin Pract 2000;50: 153-9.
8. Lecube A, Sampol G, Muñoz X, Hernández C, Mesa J, Simó R. Type 2 diabetes impairs pulmonary function in morbidly obese women. A case-control study. Diabetologia 2010;53:1210-6.
9. Lecube A, Sampol G, Muñoz X, Lloberes P, Hernández C, Simó R. Insulin resistance is related to impaired lung function in morbidly obese women: a case-control study. Diabetes Metab Res Rev 2010;26:639-45.
10. Lecube A, Sampol G, Muñoz X, Ferrer R, Hernández C, Simó R. TNF-α system and lung function impairment in obesity. Cytokine 2011;54:121-4.
11. Vara E, Arias-Díaz J, García C, Balibrea JL, Blázquez E. Glucagon-like peptide-1(7-36) amide stimulates surfactant secretion in human type 2 pneumocytes. Am J Respir Crit Care Med 2001;163:840-6.
12. Ahrén B. GLP-1 and extra-islet effects. Horm Metab Res 2004;36:842-5.
13. Vgontzas A, Legro R, Bixler E, Grayev A, Kales A, Chrousos GP. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab 2001;86:517-20.
14. Ramadan W, Dewasmes G, Petitjean M, Wiernsperger N, Delanaud S, Geloen A, et al. Sleep apnea is induced by a high-fat diet and reversed and prevented by metformin in non-obese rats. Obesity (Silver Spring) 2007;15:1409-18.
15. Lecube A, Sampol G, Lloberes P, Romero O, Mesa J, Hernández C, et al. Diabetes is an independent risk factor for severe nocturnal hypoxemia in obese patients. A case-control study. PloS One 2009;4:e4692.
16. Lecube A, Sampol G, Hernández C, Romero O, Ciudin A, Simó R. Characterization of sleep breathing pattern in patients with type 2 diabetes: Sweet Sleep Study. PLoS One 2015;10:e0119073
17. Lecube A, Ciudin A, Sampol G, Valladares S, Hernández C, Simó R. Effect of glycemic control on nocturnal arterial oxygen saturation: A case-control study in type 2 diabetes patients. J Diabetes 2015;7:133-8.

NEUROPATÍA AUTONÓMICA DIABÉTICA

1. American Diabetes Association, American Academy of Neurology. Consensus statement: report and recommendations of the San Antonio conference on diabetic neuropathy. Diabetes Care 1988;11(7):592-7.
2. Arezzo JC. New developments in the diagnosis of diabetic neuropathy. Am J Med 1999;107(2B):S9-16.
3. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2015;38(1):68-9.
4. Collado Márquez S, Vegas Jáudenes I, Delgado Cortés S, De Miguel Ballano A, Escortell Mayor E, Saá Requejo C. Neuropatía autonómica diabética diagnosticada mediante un test cardiovascular en pacientes con diabetes tipo 2. Aten Primaria 2008;40(10):511-5.
5. Pagán Buzo FJ, Rivera Farina PV, Muñoz Moreno MF, Fernández Galante MI, Arenillas JF, Pérez Turiel J, et al. Study of the central and peripheral autonomic function in short evolutions type 2 diabetes and its risk categories. Diabetes Res Open J 2015;1(1):12-23.
6. Ewing DJ, Boland O, Neilson JM, Cho CG, Clarke BF. Autonomic neuropathy, QT interval lengthening, and unexpected deaths in male diabetic patients. Diabetologia 1991;34:182-5.
7. Ortega Millán C. Tratamiento de la neuropatía autonómica diabética. Formación Médica Continuada en Atención Primaria 2005;12(09):618-30.
8. Jones KL, Russo A, Stevens JE, Wishart JM, Berry MK, Horowitz M. Predictors of delayed gastric emptying in diabetes. Diabetes Care 2001;24(7):1264-9.

9. Erbas T, Varoglu E, Erbas B, Tastekin G, Akalin S. Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. Diabetes Care 1993;16:1511-4.
10. Nakanishi S, Yamane K, Kamei N, Okubo M, Kohno N. Erectile dysfunction is strongly linked with decreased libido in diabetic men. Aging Male 2004;7(2):113-9.

ESTUDIO PREDAPS

- Serrano R, García-Soidán FJ, Díaz-Redondo A, Artola S, Franch J, Díez J, et al.; Grupo de Estudio PREDADS. Estudio de cohortes en Atención Primaria sobre la evolución de sujetos con prediabetes (PREDAPS): fundamentos y metodología. Rev Esp Salud Publica 2013;87:121-35.
- García-Soidán FJ, Serrano Martín R, Díaz-Redondo A, Menéndez SA, Franch Nadal J, Díez J, et al. Evolución de pacientes con prediabetes en atención primaria de salud (PREDAPS): resultados de la etapa basal. Diabetes Práctica 2013;(Supl 4):S1-32.
- Giráldez-García C, García-Soidán FJ, Serrano Martín R, Carrillo L, Sangrós González FJ, Franch Nadal J, et al. Evolución de pacientes con prediabetes en atención primaria de salud (PREDAPS): resultados del primer año de seguimiento. Diabetes Práctica 2014;5(1):3-17.
- Giráldez-García C, Ávila L, Carramiñana F, Torres JL, Bedoya MJ, Martínez FJ, et al. Evolución de pacientes con prediabetes en Atención Primaria de Salud (PREDAPS): resultados del segundo año de seguimiento. Diabetes Práctica 2015;6(2):71-85.

LA DIABETES MELLITUS TIPO 2 EN EL ANCIANO. ESTUDIO DE LAS CARACTERÍSTICAS DE LOS PACIENTES DIABÉTICOS ANCIANOS EN ESPAÑA: UN AVANCE DE LOS RESULTADOS DEL ESTUDIO ESCADIANE

- Alemán JJ, Artola S, Franch J, Mata M, Millaruelo JM, Sangrós J; en nombre de la redGDPS. Recomendaciones para el tratamiento de la diabetes mellitus tipo 2: control glucémico. 2014. Disponible en: URL: http://www.redgdps.org/.
- American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl 1):S11-61
- Brown AF, Mangione CM, Saliba D, Sarkisian CA; California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 2003;51(5 Suppl Guidelines):S26580.
- Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Meneilly GS, Knip A, Tessier D. Diabetes in the elderly. Can J Diabetes 2013;37(Suppl 1):S184-90.
- Centers for Disease Control and Prevention. National Diabetes Fact Sheet, 2011: diagnosed and undiagnosed diabetes in the United States, all ages, 2010. Disponible en: URL: http://www.cdc.gov/diabetes/.
- Estrategia en diabetes del Sistema Nacional de Salud. Madrid: Ministerio de Sanidad y Consumo, 2007. [Última consulta: enero de 2015].
- Franch Nadal J, Artola Menéndez S, Díez Espino J, Mata Cases M; en representación de la Red de Grupos de Estudio de la Diabetes en Atención Primaria de la Salud. Evolución de los indicadores de calidad asistencial al diabético tipo 2 en atención primaria (1996-2007). Programa de mejora continua de calidad de la Red de Grupos de Estudio de la Diabetes en Atención Primaria de la Salud Med Clin (Barc) 2010;135(13):600-7.
- Gómez Huelgas R, Díez-Espino J, Formiga F, Lafita Tejedor J, Rodríguez Mañas L, González-Sarmiento E, et al.; en nombre del Grupo de Trabajo para el Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en el anciano. Tratamiento de la diabetes tipo 2 en el paciente anciano. Med Clin (Barc) 2013;140:134.
- International Diabetes Federation. Global guideline for managing older people with type 2 diabetes. Brussels: International Diabetes Federation; 2013.
- Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferranini E, Nauck M, et al. Tratamiento de la hiperglucemia en la diabetes tipo 2: un abordaje centrado en los pacientes. Diabetes Care 2012;35:1364-79.
- Sinclair A, Morley J, Rodríguez-Mañas L, Giuseppe Paolisso G, Tony Bayer T, Andrej Zeyfang A. Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. JAMDA 2012;13:497-502.
- Soriguer F, Goday A, Bosch-Comas A, Bordiú E, Calle-Pascual A, Carmena R, et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study. Diabetologia 2012;55:88-93.
- World Health Organization (WHO). Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneve: WHO; 1999.

ACCESIBILIDAD A LA HbA_{1C}

1. American Diabetes Association. (3) Initial evaluation and diabetes management planning. Diabetes Care 2015;38(Suppl 1): S17-9.
2. Guía de Bolsillo de la REDGEDAPS en diabetes [citado el 25 de septiembre de 2015]. Recuperado a partir de: URL: http://www.redgdps.org/index.php?idregistro=431.
3. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl 1):S62-9.
4. Nuevo algoritmo de tratamiento de la DM2, de la redGDPS [citado el 25 de septiembre de 2015]. Recuperado a partir de: URL: http://www.redgdps.org/index.php?idregistro=948.

5. Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 2011;154(8):554-9.
6. Gallagher EJ, Le Roith D, Bloomgarden Z. Review of hemoglobin A(1c) in the management of diabetes. J Diabetes 2009;1(1):9-17.
7. Sacks DB. Hemoglobin A1c in diabetes: panacea or pointless? Diabetes 2013;62(1):41-3.
8. Consensus Committee. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Diabetes Care 2007;30(9):2399-400.
9. Goberna R, Aguilar M. Documento de consenso sobre la armonización de resultados de la HbA1c en España. 4002769 AVANCES 25(1).indb-25-1-5.pdf [citado el 25 de septiembre de 2015]. Recuperado a partir de: URL: http://www.avancesendiabetologia.org/gestor/upload/revistaAvances/25-1-5.pdf.
10. Parrinello CM, Selvin E. Beyond HbA1c and glucose: the role of nontraditional glycemic markers in diabetes diagnosis, prognosis, and management. Curr Diab Rep 2014;14(11):548.
11. Martínez-Castelao A, Górriz JL, Bover J, Segura-de la Morena J, Cebollada J, Escalada J, et al. Documento de consenso para la detección y manejo de la enfermedad renal crónica. Semergen 2014;40(8):441-59.
12. Levey AS, Becker C, Inker LA. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. JAMA 2015;313(8):837-46.
13. Vassalotti JA, Centor R, Turner BJ, Greer RC, Choi M, Sequist TD, et al. A practical approach to detection and management of chronic kidney disease for the primary care clinician. Am J Med 2015. pii: S0002-9343(15)00855-4. doi: 10.1016/j.amjmed.2015.08.025. [Epub ahead of print.]

LADYDIAB. ENCUESTA A PROFESIONALES

1. Healy B. The Yentl syndrome. N Engl J Med 1991;325: 274-6.
2. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006;332:73-8.
3. Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia 2014;57:1542-51.
4. Melloni C, Berger JS, Wang TY, Gunes F, Stebbins A, Pieper KS, et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ Cardiovasc Qual Outcomes 2010;3(2):135-42.
5. Blauwet L, Hayes S, McManus D, Redberg R, Walsh M. Low rate of sex-specific result reporting in cardiovascular trials. Mayo Clin Proc 2007;82:166-70.
6. Vidaver RM, Lafleu B, Tong C, Bradshaw R, Marts SA. Women subjects in NIH-funded clinical research literature: lack of progress in both representation and analysis by sex. J Womens Health Gend Based Med 2000;9:495-504.
7. Geller S, Koch A, Pellettieri B, Carnes M. Inclusion, analysis, and reporting of sex and race/ethnicity in clinical trials: have we made progress? J Womens Health 2011;20:315-20.
8. Velasco S. Recomendaciones para la práctica clínica con enfoque de género. Madrid: Observatorio de Salud de la Mujer, Dirección General de la Agencia de Calidad del Sistema Nacional de Salud, Ministerio de Sanidad y Política Social. 2009.
9. Ariño D, Tomás C, Eguiluz M, Samitier M, Oliveros T, Yago T, et al. ¿Se puede evaluar la perspectiva de género en los proyectos de investigación? Gac Sanit 2011;25:146-50.
10. Manierre M. Gaps in knowledge: tracking and explaining gender differences in health information seeking. Soc Sci Med 2015;128:151-8.
11. Peyrot M, Burns K, Davies M, Forbes A, Hermanns N, Holt R, et al. Diabetes Attitudes Wishes and Needs 2 (DAWN2): a multinational, multi-stakeholder study of psychosocial issues in diabetes and person-centred diabetes care. Diabetes Res Clin Pract 2013;99:174-84.
12. Bootle S, Skovlund S; editorial group of the 5th DAWN International Summit. Proceedings of the 5th International DAWN Summit 2014: acting together to make person-centred diabetes care a reality. Diabetes Res Clin Pract 2015;109:6-18.

LAS ACTITUDES Y DIFERENCIAS EN LA ATENCIÓN A LA MUJER CON DIABETES. LADYDIAB. ESTUDIO CUALITATIVO

1. Strom Williams JL, Lynch CP, Winchester R, Thomas L, Keith B, Egede LE. Gender differences in composite control of cardiovascular risk factors among patients with type 2 diabetes. Diabetes Technol Ther 2014;16(7):421-7.
2. Baviera M, Santalucia P, Cortesi L, Marzona I, Tettamanti M, Avanzini F, et al. Sex differences in cardiovascular outcomes, pharmacological treatments and indicators of care in patients with newly diagnosed diabetes: Analyses on administrative database. Eur J Intern Med 2014;25(3):270-5.
3. Corrao S, Santalucia P, Argano C, Djade CD, Barone E, Tettamanti M, et al. Gender-differences in disease distribution and outcome in hospitalized elderly: data from the REPOSI study. Eur J Intern Med 2014;25(7):617-23.
4. Flink L, Mochari-Greenberger H, Mosca L. Gender differences in clinical outcomes among diabetic patients hospitalized for cardiovascular disease. Am Heart J 2013;165(6):972-8.

5. Kautzky-Willer A, Stich K, Hintersteiner J, Kautzky A, Kamyar MR, Saukel J, et al. Sex-specific-differences in cardiometabolic risk in type 1 diabetes: a cross-sectional study. Cardiovasc Diabetol 2013;12:78.
6. Santalucia P, Pezzella FR, Caso V. Call for Research on Women on behalf of Women Stroke Association. Eur J Intern Med 2014;25(4):e52.
7. Wexler DJ, Grant RW, Meigs JB, Nathan DM, Cagliero E. Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care 2005;28(3):514-20.
8. Reeves S, Albert M, Kuper A, Hodges BD. Why use theories in qualitative research? BMJ 2008;337:a949.
9. Tuckett AG. Qualitative research sampling: the very real complexities. Nurse Res 2004;12:47-61.
10. Fontanella BJ, Ricas J, Turato ER. Saturation sampling in qualitative health research: theoretical contributions. Cad Saude Publica 2008;24(1):17-27.
11. Carlsen B, Glenton C. What about N? A methodological study of sample-size reporting in focus group studies. BMC Med Res Methodol 2011;11:26.
12. Bryman A. Social Research Methods. 3rd ed. Oxford: Oxford University Press; 2008.
13. MacLean LM, Meyer M, Estable A. Improving accuracy of transcripts in qualitative research. Qual Health Res 2004;14(1):113-23.
14. Pope C, Ziebland S, Mays N. Qualitative research in health care. Analysing qualitative data. BMJ 2000;320(7227):114-6.

EL PIE DIABÉTICO, UNA REALIDAD QUE DEBEMOS AFRONTAR

1. Joslin EP. Menace of diabetic gangrene. N Engl J Med 1934;211:16-20.
2. World Health Organization. WHO Study Group on Prevention of Diabetes Mellitus. WHO technical report series; 844. Geneve: World Health Organization; 1994.
3. Prompers L, Schaper N, Apelqvist J, Edmons M, Jude E, Mauricio D, et al. Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study. Diabetologia 2008;51(5):747-55.
4. http://www.idf.org/diabetesatlas/update-2014]. [Última consulta: 6 de septiembre de 2015].
5. Soriguer F, Goday A, Bosch-Comas A, Bordiú E, Calle-Pascual A, Carmena R, et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study. Diabetologia 2012;55:88-93.
6. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet 2005;366:1719-24.
7. International Consensus on the Diabetic Foot and Practical Guidelines on the Management and Prevention of the Diabetic Foot by the International Working Group on the Diabetic Foot (IWGDF)/Consultative Section of the IDF. 2007. Actualized in 2011 & 2015. En: http://iwgdf.org/guidelines [Última consulta: 6 de septiembre de 2015].
8. Pavicic T, Korting HC. Xerosis and callus formation as a key to the diabetic foot syndrome: dermatologic view of the problem and its management. JDDG 2006;4:935-41.
9. Reiber GE, Boyko EJ, Smith DG. Lower extremity foot ulcers and amputations in diabetes. In: Harris MI, Cowie C, Stern MP (eds.) Diabetes in America. 2nd ed. (NIH publ. no. 95-1468). Washington DC: U.S. Government Printing Office; 1995; Chapter 18: 409-28.
10. López-de Andrés A, Martínez-Huedo MA, Carrasco-Garrido P, Hernández-Barrera V, Gil-de-Miguel A, Jiménez-García R. Trends in lower-extremity amputations in people with and without diabetes in Spain, 2001-2008. Diabetes Care 2011;34(7):1570-6.
11. Diabetic foot problems: Prevention and management NICE guidelines 2015 [NG19] Published date: August 2015. En: https://www.nice.org.uk/guidance/ng19 [Última consulta: agosto de 2015].
12. Bradbury AW. Bypass versus angioplasty in severe ischaemia of the leg (BASIL) Trial: what are its implications? Semin Vasc Surg 2009;22:267-74.
13. Graziani L, Silvestro A, Bertone V, Manara E, Andreini R, Sigala A, et al. Vascular involvement in diabetic subjects with ischemic foot ulcer: a new morphologic categorization of disease severity. Eur J Vasc Endovasc Surg 2007;33:453-60.
14. Diehm C, Allenberg JR, Pittrow D, Mahn M, Tepohl G, Haberl RL, et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation 2009;120:2053-61.
15. Schaper NC. Lessons from Eurodiale. Diabetes Metab Res Rev 2012;28(Suppl 1):S21-6.
16. Rubio JA, Aragón-Sánchez J, Lázaro-Martínez JL, Almaraz MC, Mauricio D, Antolín JB, et al.; en representación del Grupo Español del Pie Diabético (GEPID) dentro de la Sociedad Española de Diabetes (SED). Unidades de pie diabético en España: conociendo la realidad mediante el uso de un cuestionario. Endocrinol Nutr 2014;61(2):79-86.
17. Cavanagh PR, Lipsky BA, Bradbury AW, Botek G. Treatment for diabetic foot ulcers. Lancet 2005;366:1725-35.
18. Apelqvist J, Larsson J. What is the most effective way to reduce incidence of amputation in the diabetic foot? Diabetes Metab Res Rev 2000;16 (Suppl 1):S75-83.
19. Krishnan S, Nash F, Baker N, Rayman G. Reduction in diabetic amputation over 11 years in a defined UK population: benefits of multidisciplinary teamwork and continuous prospective audit. Diabetes Care 2008;31:99-101.